🔴 Veracyte is trading 4.21% down with no confirmed company catalyst

Veracyte is trading $41.34, down 4.21%, as the softer market backdrop may be weighing on shares.

• No confirmed Veracyte-specific announcement or catalyst for October 8 was found in available coverage.
• Recent company news about Decipher prostate-test research does not establish a reason for the decline.
• The supplied context shows the Nasdaq down 0.55%. Reports of elevated Treasury yields and oil may also be weighing on shares, but do not explain the full move with certainty.